Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.